New warnings for serious and life threatening side effects have been placed on the safety labels of a new class of type 2 diabetes medications, which includes the brand names Invokana, Invokamet, Jardiance, and Farxiga. The drugs, known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, work on the main site of filtered glucose reabsorption in the kidneys, resulting in the reduction of glucose reabsorption and increasing urinary excretion of glucose, thus lowering blood sugar levels in the body. A recent review by the Food and Drug Administration (FDA) into growing adverse event reports found that between March 2013 to May 2015, 73 ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.